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AbstrAct
C3G, a Guanine nucleotide Exchange Factor (GEF) for Rap1 and R-Ras, has 
been shown to play important roles in development and cancer. Previous studies 
determined that C3G regulates cell death through down-regulation of p38α MAPK 
activity. Here, we found that C3G knock-down in MEFs and HCT116 cells promotes 
migration and invasion through Rap1-mediated p38α hyper-activation. These effects 
of C3G were inhibited by Rap1 knock-down or inactivation. The enhanced migration 
observed in C3G depleted HCT116 cells was associated with reduction in E-cadherin 
expression, internalization of ZO-1, actin cytoskeleton reorganization and decreased 
adhesion. We also found that matrix metalloproteases MMP2 and MMP9 are involved 
in the pro-invasive effect of C3G down-regulation. Additionally, our studies revealed 
that both C3G and p38α collaborate to promote growth of HCT116 cells in vitro and 
in vivo, possibly by enhancing cell survival. In fact, knocking-down C3G or p38α 
individually or together promoted cell death in vitro, although only the double C3G-
p38α silencing was able to increase cell death within tumors. Notably, we found that 
the pro-tumorigenic function of C3G does not depend on p38α or Rap1 activation. 
Altogether, our studies uncover novel mechanisms by which C3G controls key aspects 
of tumorigenesis.
INtrODUctION
C3G (Crk SH3-domain-binding guanine-nucleotide-
releasing factor) is a Guanine nucleotide Exchange Factor 
(GEF) for Rap1 and R-Ras proteins [1-3] that is essential 
for embryonic development due to its function in integrin-
mediated cellular adhesion and migration [3]. 
               Research Paper
Oncotarget45061www.impactjournals.com/oncotarget
C3G has been shown to regulate cell migration in 
different ways depending on the context. For example, 
C3G deficiency enhances migration in mouse embryonic 
fibroblasts (MEFs), while it impairs cell adhesion and 
delays cell spreading [3-4]. In contrast, the absence of 
C3G or a hypermorphic C3G mutation leads to impaired 
cortical [5] and sympathetic preganglionic neurons 
migration [6], respectively. On the other hand, C3G 
overexpression leads to opposite outcomes in different 
cell types, as it increases migration of glomerulal epithelia 
cells in glomerulonephritis [7], while decreasing migration 
in highly invasive breast carcinoma cells [8]. Several lines 
of evidence suggest that C3G can exert effects through 
mechanisms that are independent of its GEF activity [9-
11].
The function of C3G in cell migration has been 
described to be mediated, at least in part, by its main target, 
Rap1 [3, 12-13]. C3G overexpression can also promote 
c-Abl-induced filopodia formation through mechanisms 
independent of its catalytic activity [14]. C3G is known to 
regulate cell-cell interactions [13, 15], where E-cadherin 
plays a key role [13]. Mechanistically, it has been found 
that C3G binds intracellular E-cadherin, and this leads to 
activation of Rap-1 and E-cadherin translocation [13]. 
The function of C3G in human cancer has been 
a subject of controversy for many years. In mouse 
fibroblasts, C3G can act as a tumor suppressor gene, as 
it prevents malignant transformation induced by several 
oncogenes [9-10,16]. Accordingly, C3G expression is 
reduced in cervical squamous cell carcinoma [17]. In 
contrast, elevations in C3G expression have been found 
in human non-small-cell lung cancer [18]. The expression 
of the p87C3G isoform in chronic myeloid leukemia 
(CML) cells has been causally associated with disease 
development [19]. Recent data also suggested that C3G, 
acting through Rap1, induces invasion of epithelial 
ovarian cancer cells and promotes the secretion of matrix 
metalloproteases MMP2 and MMP9 [20]. In colon 
carcinoma, the C3G gene is frequently demethylated [21], 
but it remains to be determined whether this epigenetic 
modification is associated with changes in C3G expression 
or if it plays any relevant role in the progression of this 
cancer. 
There is extensive evidence for the involvement of 
p38α MAPK in cancer. Like C3G, p38α has been shown 
to act also both as a tumor suppressor or tumor promoter 
depending on the type of cancer and tumor stage [22]. 
p38α was found to inhibit tumor initiation by promoting 
cell cycle arrest and/or inducing apoptosis [22-24]. In 
contrast, increased levels of phosphorylated (active) 
p38α have been correlated with malignancy in various 
cancer types [22], such as head and neck carcinoma 
[25]. It has been also reported that at late stages of 
tumor development, p38α can promote cell survival [22, 
26], migration and invasion, thereby contributing to the 
metastatic dissemination of cancer cells [22]. Accordingly, 
p38α MAPK is required for cell migration in MEFs [27], 
and several cancer cell lines [22, 28]. Moreover, p38α 
negatively regulates cell adhesion in embryonic stem 
cells [29] and cardiomyocyte-derived cell lines [30], 
which would result in an enhanced migratory phenotype. 
We have recently reported that p38α promotes growth of 
HCT116 colon cancer cells in vitro and in nude mice, as 
well as positively regulates migration and invasion [27]. In 
agreement with these findings, recent studies highlighted a 
fundamental role for p38α in promoting cell proliferation 
and survival in a mouse model of colitis-associated tumor 
induction [31].
Using the CML cell line K562 and MEFs deficient in 
p38α and/or C3G, we have previously reported that C3G, 
through down-regulation of p38α activity, positively or 
negatively regulates apoptosis, depending on the stimulus 
[32-33]. C3G and p38α also display antagonistic roles in 
the regulation of focal adhesion (FA) complex formation 
in K562 cells [34]. Based on these previous findings, in the 
present study we wished to determine if p38α could also 
mediate the effect of C3G on cell migration and invasion. 
In addition, we investigated if the C3G/p38α pathway 
could be potentially involved in tumor growth. Our results 
revealed that C3G inhibits cell migration and invasion by 
interfering with Rap1-mediated p38α activation. On the 
other hand, both C3G and p38α are capable of promoting 
colon carcinoma tumor growth mainly through different 
mechanisms. 
rEsULts
c3G silencing increases migration and invasion of 
MEFs through a mechanism dependent on p38α 
MAPK 
In the first set of experiments, we took advantage of 
loss-of-function approaches to establish the involvement 
of C3G and p38α in MEF cell motility. As shown in Figure 
1A and 1B, wound healing assays revealed that C3G 
knock-down enhanced cell migration in wt MEFs, but not 
in p38α-/- cells. Moreover, time-lapse microscopy analysis 
showed that C3G knock-down MEFs expressing p38α lost 
cell-cell interactions, escaped from the wound border, and 
moved away (Suppl. Videos). In contrast, MEFs lacking 
p38α moved slowly and collectively, maintaining cell-cell 
interactions, and in these cells, C3G knock-down has not 
a major effect.
To determine if C3G was acting through its main 
target, Rap1, we evaluated the effect of a dominant 
negative Rap1 (DNRap1) construct using a MEFs cell line 
previously established, where Rap1-GTP levels are very 
low [33]. Figure 1A and 1B show a reduction in migration 
in wt cells expressing DNRap1, which correlates with 
the reduction in phospho-p38α levels (Suppl. Fig 1). In 
Oncotarget45062www.impactjournals.com/oncotarget
p38α-/- MEFs, no significant effect was observed. To 
further demonstrate the relevance of p38α, the effect of 
the selective p38α/β inhibitor SB203580 was examined. 
Treatment with this p38 inhibitor prevented the enhancing 
effect of C3G knock-down on migration in wt MEFs 
and decreased the migratory ability of non-silenced cells 
(Figure 1C and Suppl. Figure 2). These results strongly 
indicate that p38α mediates the pro-migratory effect 
caused by C3G silencing. 
Next, we evaluated the effect of C3G on invasion. 
C3G knock-down markedly enhanced invasion of wt 
MEFs through Matrigel, but not that of p38α-/- cells 
(Figure 2A and 2B). Cells lacking p38α had a very 
low invasive capacity. Moreover, the expression of the 
DNRap1 impaired invasion of wt MEFs. These results 
indicate that the increased invasion induced by C3G 
depletion requires p38α activation. This was further 
supported by the inhibitory effect of SB203580 on the 
invasive effect on Matrigel (Figure 2C) and collagen (data 
not shown) caused by C3G knock-down. 
MMPs are relevant for extracellular matrix 
degradation during migration and invasion [35-36], and 
some of them are regulated by p38α, such as MMP2 and 
MMP9 [27, 37]. As shown in Figure 2D, MMP2 and 
MMP9 activities were higher in wt than in p38α-/- MEFs, 
and they were further increased upon C3G knock-down in 
wt MEFs. In contrast, activities of these MMPs decreased 
in wt cells expressing DNRap1. In addition, treatment 
with SB203580 markedly reduced MMP9 activity in wt 
cells, with or without C3G silencing, and slightly inhibited 
MMP2 activity (Suppl. Figure 3). These data suggest the 
involvement of MMP2 and MMP9 in the pro-invasive 
effect caused by C3G knock-down as well as in the 
inhibitory effect of DNRap1.
Figure 1: C3G knock-down enhances migration of MEFs through a mechanism dependent on p38α. Wound healing assay. 
MEFs (wt and p38α-/-, with (shC3G) or without C3G knock-down or expression of DNRap1 (DNRap1)) were maintained in the absence of 
serum and allowed to migrate. A. Representative images from phase contrast microscope after 0 and 8h of migration. B. and C. Histograms 
show the mean ± S.E.M. of the percentage of wound closure (n = 4). ++p < 0.01 and +++p < 0.001, versus wt; **p< 0.01; ***p < 0.001, 
compared as indicated. C. Effect of p38α/β inhibition with the chemical inhibitor, SB203580 (10µM), on cell migration. 
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c3G knock-down enhances migration and 
invasion of Hct116 cells through a mechanism 
dependent on p38α
Figure 2: C3G silencing increases the invasive capacity of MEFs by a mechanism mediated by p38α and dominant 
negative Rap1 impairs invasion. MEFs (wt and p38α-/-, with (shC3G) or without C3G knock-down or expression of DNRap1 
(DNRap1)) were maintained in the absence of serum for the last 24h. A., B. and C. Invasion through Matrigel using FBS (10%) as 
chemoattractant. A. Representative images of invading cells after staining with crystal violet (phase contrast microscope). B. and C. 
Histograms show the mean value ± S.E.M. of the percentage of invading cells (n = 4). ++p < 0.01 and +++p< 0.001, versus wt; **p < 0.01, 
compared as indicated. C. Effect of p38α/β inhibition with SB203580 (10µM) on cell invasion. D. Zymographic analysis of MMP2 and 
MMP9 activities using gelatin as the substrate and FBS as a control. Representative zymogram (left panel). Histogram (right panel) 
showing the mean ± S.E.M. of the densitometric analysis of gelatinase areas expressed as fold increase of the control value (n = 6). +p < 
0.05,++p < 0.01 and +++p < 0.001, versus wt; **p < 0.01, compared as indicated. 
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C3G is known to regulate migration, invasion, as 
well as the tumorigenic activity of various cancer cell 
types [8, 15, 17-20]. However, the functional relevance 
of C3G in colon carcinoma has not been characterized. 
First, we examined C3G protein levels in human colon 
carcinoma cell lines with different invasive capacities: 
HCT116 cells (low invasive ability), SW480 and SW620 
cells (high invasive ability). As shown in Figure 3A, the 
highest C3G expression levels were found in the least 
invasive cell line, HCT116 cells, thus suggesting an 
inverse correlation between C3G protein levels and colon 
carcinoma cells invasive capacity. Next, we determined 
the effect of C3G down-regulation on the migratory and 
invasive capacities of HCT116 cells. Notably, knocking-
down C3G in parental cells led to a significant up-
regulation of the levels of phospho-p38α, phospho-Akt 
and phospho-ERKs in response to serum (Figure 3B), 
as previously described in MEFs [33]. Hence, we next 
determined the effect of C3G knock-down on migration 
and whether this effect was dependent on p38α. Figure 3C 
shows that C3G silencing enhanced migration in HCT116 
cells expressing p38α, but not in those subjected to p38α 
depletion. Moreover, inhibition of p38α/β with SB203580 
prevented the enhancement of migration induced by C3G 
knock-down in cells expressing p38α (Figure 3C) and 
reduced the migratory capacity of non-silenced cells. 
These results suggest that C3G inhibits migration through 
p38α inhibition.
To assess if the effects of C3G were mediated by 
Rap1, Rap1 was knocked-down in parental HCT116 
cells using two different shRNAs. Figure 3D shows that 
Rap1 levels were significantly reduced by both shRNAs, 
which reduced migration. This suggests that Rap1 does 
not mediate C3G effects on migration. To confirm this, 
Rap1 was transiently knocked-down in C3G silenced 
HCT116 cells. Surprisingly, Rap1 knock-down prevented 
the increase in migration induced by C3G knock-down in 
cells expressing p38α (Figure 3E), in a similar way that 
p38α/β inhibition did. Accordingly, phospho-p38 MAPK 
levels markedly decreased upon Rap1 knock-down in cells 
expressing p38α, either with or without C3G silencing 
(Figure 3F). These results indicate that in the absence of 
C3G, compensatory mechanisms are activated and other 
Rap1 GEFs could possibly activate Rap1. This would lead 
to increase p38α activation and consequently, enhance 
migration. 
We also found that C3G knock-down reduced 
adhesion of HCT116 cells expressing p38α (Figure 
4A), which was prevented by Rap1 knock-down (Suppl. 
Figure 4). Both single p38α and Rap1 depletion increased 
adhesion, as also observed upon inhibition of p38α/β 
with SB203580 (Figure 4B). Indeed, C3G knock-down 
cells expressing p38α showed the lowest adhesion, which 
might favor migration. Accordingly, invasion of these 
cells through Matrigel using HGF as chemoattractant 
was increased (Figure 4C), and this effect was dependent 
on p38α activation, as p38α knock-down or SB203580 
impaired the invasive response (Figure 4C). Similarly, 
Rap1 knock-down abrogated invasion of parental cells 
(Figure 4D) and impaired the pro-invasive effect caused 
by C3G silencing (Figure 4E).
MMP2 and MMP9 activities were higher in 
HCT116 cells expressing p38α relative to p38α knock-
down cells (Figure 4F). These differences were further 
increased upon C3G silencing (Figure 4F). In contrast, 
Rap1 knock-down decreased MMP2 and MMP9 activities 
in cells expressing p38α (Suppl. Figure 5). Other MMPs 
reported to be important for invasion of colon carcinoma 
cells (MMP7, MMP10 and MMP13) did not show any 
significant change in expression as a consequence of C3G 
and/or p38α knock-down, as determined by RT-qPCR 
(data not shown). 
Mechanisms involved in the regulation of 
migration by c3G
Cell migration involves the re-organization of 
F-actin cytoskeleton and the generation of structures 
such as ruffles, filopodia and lamellipodia [38]. These 
effects can be regulated by p38α [28]. Changes in the 
expression and/or subcellular localization of cell-cell 
contact proteins also occur during migration [38-40]. To 
gain further insights into the mechanisms involved in the 
regulation of migration and invasion by C3G, we analyzed 
F-actin cytoskeleton organization, as well as the levels and 
subcellular localization of relevant cell junction proteins, 
namely E-cadherin and ZO-1. 
E-cadherin is known to interact with C3G, which 
participates in the maturation of E-cadherin-based cell-
cell contacts [41-42]. E-cadherin levels were substantially 
reduced in HCT116 cells subjected to C3G knock-down 
(Figure 5A), with or without p38α depletion. Silencing 
p38α also led to E-cadherin down-regulation, and 
indeed, the largest reduction in E-cadherin levels was 
observed in cells with double C3G-p38α knock-down. 
As this reduction in E-cadherin did not correlate with the 
migratory and invasive capacity of the cells (see Figure 3C 
and 4C), we analyzed changes in E-cadherin subcellular 
localization by confocal microscopy. In all cases, 
E-cadherin was primarily located in the plasma membrane 
(Figure 5B), although it was partially internalized in cells 
subject to dual knock-down.
 Although no significant changes in ZO-1 total 
protein levels could be observed upon C3G knock-down 
in cells expressing p38α (Figure 5A), this protein was 
found to be internalized (Figure 5B). In contrast, in p38α 
silenced HCT116 cells, ZO-1 was mainly present in the 
plasma membrane, as also observed in cells subjected to 
double C3G/p38α knock-down, where ZO-1 total levels 
were reduced (Figure 5A and 5B). These data suggest that 
cell-cell contacts, particularly tight junctions, are partially 
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Figure 3: C3G knock-down enhances migration of HCT116 cells by increasing Rap1-mediated p38α activation. HCT116 
(non-silenced (-) and p38α knock-down (shp38α); with (shC3G) or without C3G knock-down; with (shRap1(1) and shRap1(2)) or without 
Rap1 knock-down), SW480 and SW620 cells were used. A. C3G protein expression in HCT116, SW480 and SW620 cells analyzed by 
Western-blot and normalized with β-actin. B. Western-blot analysis of P-Akt, P-ERKs and P-p38 MAPK levels normalized with β-actin. 
p38α and C3G were measured as a control of their expression. C. Wound healing assays. Left panel, representative images from phase 
contrast microscope after 0 and 48h of migration, in the absence or presence of p38α/β inhibitor, SB203580 (10µM). Right panel, the 
histogram shows the mean ± S.E.M. of the percentage of wound closure (n = 4). *p < 0.05,**p < 0.01; ***p < 0.001, versus non-silenced 
cells; ++p < 0.01, compared as indicated. D. Effect of Rap1 knock-down using two different shRNAs. Left panel, representative images from 
phase contrast microscope after 0 and 48h of migration upon transient Rap1 silencing using one of the shRNAs against Rap1. Right panel, 
Rap1 protein expression analyzed by Western-blot and normalized with β-actin (upper site) and histogram (lower site) showing the mean ± 
S.E.M. of the percentage of wound closure using the two different shRNAs against Rap1 (n = 4). *p < 0.05,**p < 0.01 versus non-silenced 
cells. E. Effect of C3G and Rap1 double knock-down on wound healing closure. Rap1 protein expression analyzed by Western-blot and 
normalized with β-actin (upper panel) and histogram (lower panel) showing the mean ± S.E.M. of the percentage of wound closure (n = 
3). **p < 0.01 and ***p < 0.001, versus non-silenced cells; ++p < 0.01, compared as indicated. F. Analysis of p38α activation. Western-blot 
analysis of P-p38 MAPK, p38α and Rap1 levels normalized with β-actin in cells expressing p38α. 
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Figure 4: C3G silencing promotes invasion of HCT116 cells by a mechanism mediated by p38α, but not by Rap1. Effect 
of C3G knock-down on adhesion. HCT116 cells (non-silenced (-) and p38α knock-down (shp38α); with (shC3G) or without C3G knock-
down; with (shRap1) or without Rap1 knock-down) were maintained in the presence (adhesion assays) or absence (invasion assays) of 
serum and in the presence or absence of the p38α/β inhibitor, SB203580 (5µM). A. and B. Adhesion assays. Histograms show the mean ± 
S.E.M. of the number of adhered cells 1h after platting. C. and D. Invasion through Matrigel using HGF as chemoattractant. Left panels, 
representative images of invading cells after staining with crystal violet (phase contrast microscope). Right panels, histograms showing 
the mean value ± S.E.M. of the percentage of invading cells referred to non-silenced (100%) (n = 4). **p < 0.01, ***p < 0.001, versus 
non-silenced cells; ++p < 0.01, compared as indicated. E. Effect of C3G and Rap1 double knock-down on invasion through Matrigel. The 
histogram shows the mean value ± S.E.M. of the percentage of invading cells referred to non-silenced (100%).n = 3). *p < 0.05, **p < 
0.01, ***p < 0.001, versus non-silenced cells; +p < 0.05, compared as indicated. F. Zymographic analysis of MMP2 and MMP9 activities 
using gelatin as the substrate and FBS as a control. Representative zymogram (upper panel). Histogram (lower panel) showing the mean ± 
S.E.M. of the densitometric analysis of gelatinase areas expressed as fold increase of the control value (n = 4). *p < 0.05, **p < 0.01, versus 
non-silenced cells. 
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Figure 5: Effect of C3G knock-down on actin-organization, E-cadherin and ZO-1 expression and their subcellular 
localization in HCT116 cells. Function of p38α MAPK. HCT116 cells (non-silenced (-) and p38α knock-down (shp38α); with 
(shC3G) or without C3G knock-down) were used. A. Representative western-blot analysis of E-cadherin and ZO-1 levels normalized with 
β-actin. The ratios E-cadherin/β-actin and ZO-1/β-actin of the densitometric analyses are shown. B. Representative confocal microscopy 
images of E-cadherin, ZO-1 and actin staining, using specific antibodies or phalloidin, respectively. Scale bar = 20µm. Arrows indicates 
the presence of filopodia.
Oncotarget45068www.impactjournals.com/oncotarget
disrupted in C3G knock-down HCT116 cells expressing 
p38α, which would result in enhanced migration. 
We also examined F-actin cytoskeleton organization 
by confocal microscopy. As shown in Figure 5B, the 
presence of filopodia and lamellipodia was highly 
noticeable in C3G knock-down HCT116 cells expressing 
p38α (see arrows), an effect that correlates with the 
enhanced migratory capacity of these cells.
C3G and p38α MAPK promote HCT116 cells 
foci formation and in vivo tumor growth through 
independent mechanisms
Anchorage-dependent growth assays revealed a 
reduction in the number of foci in C3G knock-down 
cells, which was more prominent in cells expressing p38α 
(Figure 6A). The number of foci was also reduced as a 
consequence of p38α silencing. These results suggest that 
Figure 6: C3G and p38α MAPK, but not Rap1, promote anchorage dependent growth of HCT116 cells. HCT116 cells 
(non-silenced (-) and p38α knock-down (shp38α); with (shC3G) or without C3G knock-down; with (shRap1(1) and shRap1(2)) or without 
Rap1 knock-down) were used. The effect of p38α/β inhibition by SB203580 (10µM) was also assessed. Anchorage dependent growth 
assays. . Histograms show the mean ± S.E.M. of foci number A. and D. or the number of cells per focus (n = 4) B.. A. and B. *p < 0.05,**p 
< 0.01,***p < 0.001, compared as indicated. C. Representative images of individual foci. D. Effect of C3G, Rap1 and C3G-Rap1 double 
knock-down on foci formation. **p < 0.01, ***p < 0.001, versus non-silenced cells; ++p < 0.01 and +++p < 0.001, compared as indicated (n 
= 3).
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both C3G and p38α promote foci formation probably 
through distinctive pathways. Moreover, inhibition of 
p38α with SB203580 reduced the number of foci in non-
silenced cells, thus recapitulating the effect of p38α knock-
down (Figure 6A). Surprisingly, in C3G depleted cells, 
the foci number was increased in response to SB203580 
treatment, while having no effect on double C3G-p38α 
knock-down cells. To gain further insights into the 
function of C3G and p38α in foci formation, the number of 
cells per focus and its morphology was assessed. As shown 
in Figure 6B, both C3G and p38α knock-down decreased 
the number of cells per focus, whereas SB203580 only 
caused a reduction in non-silenced cells. Moreover, the 
foci formed by C3G knock-down cells, particularly those 
expressing p38α, showed a reduction in cell-cell contacts, 
resulting in cell dispersion (Figure 6C), as expected from 
the role of C3G in adhesion and migration. 
We next asked if Rap1 mediated C3G actions on foci 
formation. Single Rap1 knock-down led to a significant 
increase in the number of foci in p38α knock-down 
HCT116 cells, but not in cells expressing p38α (Figure 
6D). Rap1 depletion also increased the number of foci in 
C3G knock-down cells, not only in the absence of p38α, 
but also in its presence. This indicates that Rap1 does not 
mediate C3G effects on anchorage-dependent growth. 
Next, we analyzed the effect of C3G on anchorage-
independent growth. The number of foci was highly 
reduced upon C3G knock-down, p38α knock-down, 
Figure 7: C3G and p38α MAPK promote tumor growth of HCT116 cells, while Rap1 does not. HCT116 cells (non-silenced 
(-) and p38α knock-down (shp38α); with (shC3G) or without C3G knock-down; with (shRap1(1) and shRap1(2)) or without Rap1 knock-
down) were used. A. and C. Anchorage independent growth of HCT116 cells at 14 days, in the absence or presence of SB203580 (10µM), 
as indicated. Histograms show the mean value ± S.E.M. of the foci number expressed as the fold increase of non-silenced cells (n = 4). 
*p < 0.05, **p < 0.01, ***p < 0.001 as compared with non-silenced cells, or as indicated. B. Representative images of individual foci. D. 
Xenograft assay. Immunodeficient mice were injected subcutaneously with HCT116 cells. Tumor size was calculated by the formula ((L/2)
x(W/2))xπ, where L and W are the longest and the shortest diameter in centimeters, respectively. Graphs show the mean value ± S.E.M. of 
tumor size at the indicated time points (n = 6). ***p < 0.001 versus non-silenced cells.
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double C3G-p38α-knock-down or p38α inhibition with 
SB203580 (Figure 7A). However, the largest reduction 
in the number of foci was observed in C3G depleted 
HCT116 cells expressing p38α. Moreover, foci generated 
by non-silenced HCT116 cells are larger in size (Figure 
7B). Curiously, C3G-p38α double knock-down cells foci 
seemed to have less and more dispersed cells. On the other 
hand, foci number was increased upon Rap1 knock-down 
(Figure 7C), mainly in p38α knock-down HCT116 cells, 
as observed in anchorage-dependent assays. 
Figure 8: Analysis of E-cadherin, ZO-1 and cell death in tumors derived from C3G, p38α and C3G-p38α knock-down 
HCT116 cells. End point tumors generated from HCT116 cells (non-silenced (-) and p38α knock-down (shp38α); with (shC3G) or 
without C3G knock-down) were analyzed. A. E-cadherin (green) and B. ZO-1 (brown) staining using specific antibodies. Inserts in A. 
show a higher amplification of images. C. Dead cells detected by Tunel assay (brown). D. Histogram showing the mean value ± S.E.M. of 
the percentage of Tunel positive areas per tumor. *p < 0.05 versus non-silenced cells. Scale bars: E-cadherin 30µm (inserts 10µm); ZO-1 
20µm; Tunel assay 50 µm.
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Finally, we assessed the involvement of C3G on 
the tumorigenic activity of HCT116 cells in nude mice. 
Upon subcutaneous inoculation of control HCT116 cells, 
tumors were readily visible at 14 days and progressively 
grew over time (Figure 7D). Interestingly, tumor size was 
significantly reduced in cells subject to either C3G or p38α 
knock-down. Tumor growth was almost undetectable in 
cells with double C3G -p38α knock-down. 
To further understand the mechanisms involved in 
the in vivo regulation of tumor growth, we analyzed the 
morphology of tumor cells, as well as the presence of 
stromal cells and dead cells within the tumors. E-cadherin 
(Figure 8A) and ZO-1 (Figure 8B) expression decreased 
in xenografts derived from C3G, p38α or C3G-p38α 
double silenced HCT116 cells. Additionally, E-cadherin 
was partially internalized in C3G knock-down cells 
(Figure 8A), which is consistent with the migration and 
invasion data. This disruption of cell-cell interactions 
might also contribute to the impaired tumor formation. 
We also found a higher number of Tunel positive cells in 
C3G-p38α double knock-down HCT116-derived tumors 
(Figure 8C and 8D), with almost 70% of apoptotic cells 
in the small nodules. This suggests that depletion of C3G 
and p38α together sensitize cells to apoptotic stimuli, 
ultimately resulting in the inhibition of tumor formation. 
In agreement with this, oxidative stress (H2O2) markedly 
reduced in vitro cell viability in these cells, with a 
magnitude larger than in single C3G or p38α knock-down 
HCT116 cells (Suppl. Figure 6). The lack of attachment 
also increased apoptosis in C3G-p38α double knock-down 
cells in vitro, although single C3G silencing had a greater 
effect (Suppl. Figure 7).
Finally, we observed elevated fibroblast infiltration 
in tumors with either C3G and/or p38α silencing (Figure 
9A), whereas macrophage infiltration was decreased 
(Figure 9B). Furthermore, angiogenesis was clearly 
increased upon inhibition of p38α, as revealed by the 
increase in vessel density using by Meca 32 staining, and 
Figure 9: Analysis of infiltrated cells in tumors derived from C3G, p38α and C3G-p38α knock-down HCT116 cells. End 
point tumors generated from HCT116 cells (non-silenced (-) and p38α knock-down (shp38α); with (shC3G) or without C3G knock-down) 
were analyzed. A. αSMA (brown), B. CD14 (green) and C. MECA32 (green) staining using specific antibodies. Scale bars: αSMA 50µM; 
CD14 20µM; MECA32 30µM.
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this effect was independent of C3G (Figure 9C). 
DIscUssION
The function of C3G in cell migration has not 
been well characterized, although a number of studies 
indicate that it can play distinct specific roles depending 
on the context [3-6, 8]. For example, C3G deficient MEFs 
exhibited increased migration [3-4]. Accordingly, C3G 
overexpression reduced cell migration of highly invasive 
breast carcinoma cells [11]. In contrast, C3G/Rap1 
pathway mediates IGF-1-induced migration of MCF-
7 breast cancer cells [43]. In this study, we demonstrate 
that in MEFs and HCT116 colon carcinoma cells, 
C3G down-regulates migration and invasion through a 
mechanism dependent on p38α. In fact, C3G silencing 
enhances migration/invasion through the up-regulation of 
p38α activity, which was impaired upon Rap1 silencing. 
Therefore, our results indicate that under physiological 
conditions, C3G decreases migration and invasion through 
a mechanism that interferes with Rap1-dependent p38α 
activation. This could involve specific protein-protein 
interactions rather than a GEF dependent mechanism [9-
11, 16, 34], such as a direct C3G and p38α interaction, as 
observed in CML cells [34]. However, upon C3G down-
regulation, other Rap1 GEFs [13, 42] would enhance Rap1 
activation as a compensatory mechanism, leading to p38α 
Figure 10: Scheme showing the interplay between C3G, p38α and Rap1 to regulate cell migration, invasion and tumor 
growth of HCT116 cells. Upper panel, the diagram shows that C3G inhibits cell migration and invasion through down-regulation 
of p38α activity, either by preventing Rap1-mediated p38α activation by other Rap1GEFs or through p38α inhibition by alternative 
mechanisms. p38α promotes these processes. Changes in E-cadherin and ZO-1 expression and their cellular internalization, together 
with F-actin remodeling would mediate C3G/p38α actions on migration and invasion. MMP2 and MMP9 contribute to p38α induced 
invasion. Lower panel, the diagram shows that C3G and p38α promote tumor growth probably through independent pathways, inducing 
cell survival. Additionally, C3G through activation of cell adhesion may favor tumor growth. Rap1 inhibits tumor growth mainly through 
p38α independent mechanisms, although Rap1-mediated p38α activation could also prevent tumor growth by decreasing cell adhesion.
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hyper-activation. This is supported by the fact that Rap1-
GTP levels were up-regulated in C3G-silenced MEFs 
under growing conditions or in response to certain stimuli 
such as osmotic stress (Suppl. Figure 8). 
Our findings support the concept that Rap1 
promotes cell migration and invasion, as previously 
shown in several cancer cell lines [43-49]. Accordingly, 
optimal cell migration was associated with cycles of Rap1 
activation [49]. Additionally, our data indicate that Rap1-
mediated p38α activation is required to promote migration 
and invasion. This agrees with the function of Rap1 as an 
activator of p38 in response to FGF-2 in endothelial cells 
[50]. However, Rap1 can also inhibit p38 activation [51] 
or act in a parallel pathway in other contexts [52]. 
Our results also support a central role for p38α in the 
actions of C3G on migration and invasion. We and others 
have previously shown that p38α plays roles in different 
aspects of cell migration, invasion and metastasis, favoring 
tumor progression [27, 37]. p38α mediates migration 
in HeLa cells and MEFs through the regulation of actin 
cytoskeleton via MK2 [28]. In HGF/Met-activated cortical 
neurons, the Rac1/p38 cascade is also crucial for migration 
[53]. p38α can also induce a cytoskeletal remodeling 
and a migratory response in tumor cells through Hsp27 
phosphorylation [54]. Our results indicate that C3G, 
acting through p38α, regulates actin cytoskeleton 
organization in HCT116 cells. Thus, in C3G silenced 
cells, p38α hyperactivation promotes the formation of 
filopodia and other migratory structures. In addition, 
C3G depletion induces internalization of ZO-1 and partial 
loss of E-cadherin, which disrupts cell-cell interactions 
and favors cell migration. This is also supported by in 
vivo data derived from xenografts assays, which show a 
reduction in ZO-1 and E-cadherin expression as well as 
a partial internalization of E-cadherin. In MEFs, C3G 
down-regulation also leads to a p38α-dependent actin 
reorganization (data not shown) and a loss of cell-cell 
contacts (Suppl. Video MEFs-shC3G).
In melanoma cells [22] or ovarian cancer cells [55], 
p38 MAPK promotes cell migration and invasion through 
regulation of MMP9. p38α also induces the expression 
of MMP1, MMP2, MMP9 and MMP13 in other types 
of cancer [37]. Our results indicate that C3G silencing-
mediated p38α hyperactivation increases MMP2 and 
MMP9 activities in MEFs and HCT116 colon carcinoma 
cells, which correlates with the effect on cell migration 
and invasion. This fits with our previous observations that 
p38α is a positive regulator of MMP2 and MMP9 activities 
[27]. Rap1 also activates MMP2 and MMP9 in cells 
expressing p38α, in agreement with the role of Rap1 in 
inducing MMP9 secretion and invasion in head and neck 
squamous carcinoma cells [56]. Recent published data also 
suggest that C3G, acting through Rap1, promotes invasion 
of epithelial ovarian cancer cells through induction of 
MMP2 and MMP9 secretion [20].
Our studies using HCT116 colon carcinoma cells 
also revealed a positive role for both p38α and C3G in 
promoting in vitro and in vivo tumor growth. Our data 
support the concept that C3G regulates tumor growth 
mainly through p38α independent mechanisms, which 
differs from the mechanism by which it regulates 
migratory and invasive responses. Additionally, Rap1 does 
not mediate these C3G-driven effects either, but rather 
counteracts them. Results from our in vivo studies revealed 
that C3G and p38α double knock-down lead to a larger 
reduction in tumor size relative to each individual knock-
down. However, this was not observed in anchorage-
dependent or -independent growth assays, where the 
number of foci was higher in the double knock-down 
than in C3G knock-down, although there were fewer cells 
per focus. One plausible explanation for the discrepancy 
between in vitro and in vivo results may be that in the in 
vivo context, other mechanisms may influence the C3G 
response. In fact, enhanced cell death is observed in these 
C3G-p38α knock-down-derived tumors, which may limit 
tumor development. This is also supported by the low 
viability detected in vitro in C3G-p38α silenced HCT116 
cells subjected to oxidative stress (Suppl. Figure 6) or to a 
lack of attachment (Suppl. Figure 7). However, although 
the presence of dead cells in xenografts from single C3G 
knock-down cells at the end point was quite low, apoptosis 
induced in vitro by the loss of attachment was enhanced 
in these cells. This fact, together with the low adhesion 
of these cells, might explain the impairment in tumor 
cell growth in vivo and in vitro. In fact, the low adhesion 
observed in C3G knock-down cells correlates with a low 
number of foci. p38α inhibition with SB203580 or Rap1 
knock-down counteracted this effect of C3G silencing on 
adhesion, increasing also the number of foci. Hence, Rap1-
mediated p38α hyperactivation might limit cell attachment 
and tumor growth upon C3G depletion, although other 
Rap1 independent mechanisms might contribute to the 
reduced tumor growth (Figure 10).
Overall, our data demonstrate that C3G down-
regulation promotes migration and invasion in MEFs and 
HCT116 colon carcinoma cells through a mechanism 
that requires p38α activation, and that may be mediated 
by Rap1 hyperactivation by other Rap1 GEFs (Figure 
10). Down-regulation or inactivation of Rap1 impairs 
migration and invasion as a consequence of the low 
p38α activity. On the other hand, C3G and p38α promote 
growth of HCT116 cells in vitro and in vivo, most likely 
through different mechanisms. The effect of C3G might be 
dependent on its pro-adhesive and pro-survival activities 
(Figure 10), which might allow attachment and subsequent 
proliferation and/or survival of the cells. The pro-adhesive 
effect of C3G would be partially counteracted by Rap1-
mediated p38α activation, although Rap1 would also 
inhibit tumor growth through other effectors. In addition, 
p38α might promote cell survival and/or proliferation 




cell lines and cell culture
Wt and p38α-/-mouse embryonic fibroblasts (MEFs) 
were generated in our laboratory and immortalized by 
passages. C3G was permanently silenced using a C3G 
shRNA inserted in the pSuper.retro.puro vector [33] 
and cells were selected with 2µg/ml puromycin (Sigma-
Aldrich P8833). To inhibit Rap1 function, MEFs (wt and 
p38α-deficient) expressing a Rap1 dominant-negative 
(with Ser17 mutated to Asn) were previously generated 
and selected with 2µg/ml hygromycin [33]. 
The human colorectal carcinoma HCT116 cell line 
was obtained from ATCC (CCL-247) and authenticated 
by microsatellite markers analysis. HCT116 cells with 
permanent p38α knock-down were previously generated 
using a p38α shRNA inserted in pSuper.retro.puro 
vector [58] and selected with 2µg/ml puromycin. As a 
control, cells transfected with the empty vector were also 
generated. C3G was stably knocked-down by infection 
with human C3G shRNAs Lentiviral Particles (75000 
infectious units) containing a mixture of different shRNAs 
(Santa Cruz Biotechnology sc-29863-V) in the presence 
of 10 µg/ml Polybrene (Santa Cruz Biotechnology sc-
134220) or a control shRNA for non-silenced cells. Cells 
were selected with puromycin (2µg/ml) and several clones 
were obtained, keeping those with C3G protein levels 
ranging between 30 and 40%. Different clones were used 
for the main experiments. 
Rap1 was knocked-down using two different specific 
shRNAs (shRap1(1) and shRap1(2)) against human Rap1 
(Sigma TRCN0000029784 and TRCN0000029788, 
respectively) by transient transfections (using 
Metafectene-Pro) with a plasmid carrying shRNA 1 or 2.
MEFs were grown in DMEM medium and HCT116 
cells in McCoy’s (Invitrogen) medium supplemented with 
10% fetal bovine serum (FBS) plus antibiotics at 37ºC, 5% 
CO2 in a humidified atmosphere. 
p38α and/or p38β were inhibited with SB203580 
(Calbiochem; 559389) at 5-10 µM.
Cell extracts preparation and western-blot 
analysis
Cells were lysed in a buffer containing 50 mM 
Tris·HCl (pH 7.5), 150 mM NaCl, 1% NP40, 5 mM 
EGTA, 5 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM 
Na3VO4 and 20 mM NaF and centrifuged (at 13.000 rpm 
10 min, 4°C). Supernatants (total cell extracts) were stored 
at -80°C. Protein concentration was determined by the 
Bradford method.
Western-blot analysis was carried out as previously 
described [30] using total cell extracts. Proteins were 
separated by electrophoresis using Anderson gels [59] 
(or SDS-page gels) and transferred to nitrocellulose 
membranes that were probed with the following antibodies 
against: P-p38MAPK (9211) P-ERKs (9101), P-Ser 473 
Akt (9271) from Cell Signaling Technology, C3G (H-300) 
(sc-15359), Rap1 (sc-65), p38α MAPK (sc-535) from 
Santa Cruz Biotechnology, E-cadherin (BD 610182), ZO-1 
(Invitrogen 617300) and β -actin (Sigma A5441).
Wound healing assays
Confluent cells were pre-treated with mitomycin C 
(25 μg/ml, Sigma-Aldrich M0503) for 30 min to inhibit 
cell growth. Then, a straight scratch was performed and 
the medium replaced by a fresh one without serum (for 
MEFs) or with 2% FBS (for HCT116 cells). Cells were 
maintained for 8h-48h at 37ºC and 5% CO2. Migration 
was followed by a phase-contrast microscope (Eclipse 
TE300 Nikon coupled to a digital camera) at different 
time points. Photographs were taken to quantify (using 
TScratch program) the percentage of wound healing 
closure at the different times. 
Invasion assays
Invasion was assayed using Matrigel (444 µg/
cm2) (BD Biosciences, 356234) coated transwells (8 
μm filter, BD 353097). Cells (20.000-50.000) were 
seeded in the upper chamber in a serum-free medium. 
In the lower chamber, FBS (10%) or HGF (40 ng/ml) 
was added to the medium to act as a chemoattractant. 
Then, cells were incubated for 24h at 37ºC, 5% CO2 in 
a humidified atmosphere. Medium and Matrigel from 
the upper chamber were removed and cells present in the 
lower chamber were fixed with 4% paraformaldehyde 
and stained with crystal violet 0.2% p/v (Sigma-Aldrich 
C-0775). Cells were counted using a phase-contrast 
microscope.
Quantification of MMP2/9 by zymography
To determine MMP2 and MMP9 activities, 80% 
confluent cells were serum-deprived for 24-48h and the 
culture medium was used for an electrophoresis in 8% 
SDS-polyacrylamide gels polymerized in the presence of 
0.1% gelatin under non-reducing conditions. Gels were 
washed with 2.5%Triton X-100 (30 min) to remove SDS, 
rinsed with substrate buffer (0.2 M NaCl, 5 mM CaCl2, 
1% Triton X 100, 0.02% NaN3, 50 mM Tris pH 7.5) and 
incubated in this buffer at 37ºC overnight to allow protein 
renaturation and MMP activation. To visualize gelatin 




Trypsinized HCT116 cells were resuspended in 
McCoy’s medium containing 10% FBS, seeded and kept 
in the incubator at 37 °C for 1h. After washing with PBS, 
adhered cells were stained with Crystal violet and counted 
under the microscope.
confocal microscopy analysis
The subcellular localization of E-cadherin and 
ZO-1 proteins was analyzed by confocal fluorescence 
microscopy using the same antibodies used for western 
blots. Cells were seeded on 2% gelatin-coated glass 
coverslips and fixed with 4% paraformaldehyde at 
room temperature (RT) for 30 min. F-actin staining was 
performed using rhodamine-conjugated phalloidin as 
previously described [60]. To detect ZO-1, in addition 
to fixation, cells were permeabilized with 0.1% triton 
X-100 in 0.1% BSA-PBS for 20 min [60]. Fixed cells 
were incubated in blocking solution (2 %BSA in PBS, 1 
h at RT), followed by an incubation with mouse anti-E-
cadherin or rabbit anti-ZO-1 (dilution 1:50) in 0.1% BSA 
PBS for 1 h at RT. After washing with PBS, cells were 
incubated for 1 h at RT with FITC-labelled anti-mouse or 
anti-rabbit Alexa 594 (dilution 1:200) in 0.1% BSA PBS, 
respectively. After washing with PBS, cells were prepared 
for visualization by embedding in Vectashield mounting 
medium with DAPI and visualized in a Leica TCS-SL 
confocal microscope with a 63X objective.
Focus formation assays
To measure anchorage dependent growth, 300 cells 
(HCT116 cells) were seeded in a 10 cm dish. After 8-10 
days, foci were stained with a 0.2% crystal violet solution. 
The total number of foci was quantified using Image J 
program and their size using OpenCFU program. The size 
of colonies was measured as volume applying the equation 
4/3πr3, where r is the radius of foci.
Anchorage-independent growth in soft agar
To measure anchorage-independent growth, cells 
were cultured in 24-well dishes containing two agar 
layers. Cells (3x103) were resuspended in 0.35% agar (BD, 
214530) (diluted in complete medium) and poured onto 
a 0.5% layer of agar (diluted in medium). Fresh medium 
was added to the top layer every 3 days. After 2 weeks, 
colonies were stained with 0.005% crystal violet and 
counted using a dissecting microscope. 
Xenograft assays
HCT116 cells (106 cells/100µl) were resuspended 
in McCoy’s medium and injected subcutaneously (s.c.) 
into the flank of eight-week old male nude mice (Harlam 
Laboratories). Tumor growth was monitored twice a week 
for 6 weeks. Tumor size was calculated by the formula 
((L/2)x(W/2))xπ, where L and W are the longest and the 
shortest diameter in centimeters, respectively. All animal 
experiments were carried out in compliance with the 
institutions guidelines.
Immunohistochemical and immunofluorescence 
analysis of tumor samples
Paraffin embedded sections from HCT116 tumors 
were used to detect E-cadherin (cell signaling, 3195S), 
ZO-1 (Life technologies, 339100), MECA 32 (BD 
Pharmigen, 550563), CD14 (BD Pharmigen, 553739), 
αSMA (DAKO, M0851) and cell death by Tunel (Roche, 
11093070910). For immunohistochemical analysis of 
ZO-1 and αSMA and detection of cell death by Tunel, 
endogenous peroxidase activity was first quenched. Then, 
binding of the primary antibody (ZO-1 and αSMA) was 
carried out overnight at 4ºC, followed by secondary 
antibody incubation (1h at RT), or alternatively, for 
Tunel assay, incubation for 1h at 37ºC with biotin 16-
dUTP (Roche, 11093070910) in the reaction mixture 
was performed. Finally, samples were incubated with 
the avidin/biotin reagent (Vectastain ABC Kit) for 30 
min at RT in the dark and the dAB reagent (Peroxidase 
Substrate Kit SK-4100). For immunofluorescence analysis 
of E-cadherin, MECA32 and CD14, incubation with the 
primary antibody (overnight at 4ºC) was followed by 
incubation (1 h at RT) with the secondary antibodies: 
Alexa fluor 488 Goat anti-rabbit (Life technologies, 
A11034) for E-cadherin and Alexa Fluor 488 Goat anti-
rat (Life technologies, A11006) for CD14 and MECA 32.
statistical analysis 
Data are represented as the mean values ±SEM. An 
unpaired Student’s t-test and Anova analysis were used. 
Abbreviations
MAPKs, mitogen activated protein kinase, C3G, 
Crk SH3-domain-binding guanine nucleotide-releasing 
factor, MMPs, matrix metalloproteases.
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